Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer

Authors: Agnieszka A Rawluszko, Katarzyna E Bujnicka, Karolina Horbacka, Piotr Krokowicz, Paweł P Jagodziński

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Colorectal cancer (CRC) is one of the most common and comprehensively studied malignancies. Hypoxic conditions during formation of CRC may support the development of more aggressive cancers. Hypoxia inducible factor (HIF), a major player in cancerous tissue adaptation to hypoxia, is negatively regulated by the family of prolyl hydroxylase enzymes (PHD1, PHD2, PHD3) and asparaginyl hydroxylase, called factor inhibiting HIF (FIH).

Methods

PHD1, PHD2, PHD3 and FIH gene expression was evaluated using quantitative RT-PCR and western blotting in primary colonic adenocarcinoma and adjacent histopathologically unchanged colonic mucosa from patients who underwent radical surgical resection of the colon (n = 90), and the same methods were used for assessment of PHD3 gene expression in HCT116 and DLD-1 CRC cell lines. DNA methylation levels of the CpG island in the promoter regulatory region of PHD1, PHD2, PHD3 and FIH were assessed using bisulfite DNA sequencing and high resolution melting analysis (HRM) for patients and HRM analysis for CRC cell lines.

Results

We found significantly lower levels of PHD1, PHD2 and PHD3 transcripts (p = 0.00026; p < 0.00001; p < 0.00001) and proteins (p = 0.004164; p = 0.0071; p < 0.00001) in primary cancerous than in histopathologically unchanged tissues. Despite this, we did not observe statistically significant differences in FIH transcript levels between cancerous and histopathologically unchanged colorectal tissue, but we found a significantly increased level of FIH protein in CRC (p = 0.0169). The reduced PHD3 expression was correlated with significantly increased DNA methylation in the CpG island of the PHD3 promoter regulatory region (p < 0.0001). We did not observe DNA methylation in the CpG island of the PHD1, PHD2 or FIH promoter in cancerous and histopathologically unchanged colorectal tissue. We also showed that 5-Aza-2’-deoxycytidine induced DNA demethylation leading to increased PHD3 transcript and protein level in HCT116 cells.

Conclusion

We demonstrated that reduced PHD3 expression in cancerous tissue was accompanied by methylation of the CpG rich region located within the first exon and intron of the PHD3 gene. The diminished expression of PHD1 and PHD2 and elevated level of FIH protein in cancerous tissue compared to histopathologically unchanged colonic mucosa was not associated with DNA methylation within the CpG islands of the PHD1, PHD2 and FIH genes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.CrossRefPubMed Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.CrossRefPubMed
2.
go back to reference Webb JD, Coleman ML, Pugh CW: Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci. 2009, 66 (22): 3539-3554. 10.1007/s00018-009-0147-7.CrossRefPubMed Webb JD, Coleman ML, Pugh CW: Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci. 2009, 66 (22): 3539-3554. 10.1007/s00018-009-0147-7.CrossRefPubMed
3.
go back to reference Jokilehto T, Jaakkola PM: The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med. 2010, 14 (4): 758-770. 10.1111/j.1582-4934.2010.01030.x.CrossRefPubMedPubMedCentral Jokilehto T, Jaakkola PM: The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med. 2010, 14 (4): 758-770. 10.1111/j.1582-4934.2010.01030.x.CrossRefPubMedPubMedCentral
4.
go back to reference Brahimi-Horn MC, Bellot G, Pouyssegur J: Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev. 2011, 21 (1): 67-72. 10.1016/j.gde.2010.10.006.CrossRefPubMed Brahimi-Horn MC, Bellot G, Pouyssegur J: Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev. 2011, 21 (1): 67-72. 10.1016/j.gde.2010.10.006.CrossRefPubMed
5.
go back to reference Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML: Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002, 295 (5556): 858-861. 10.1126/science.1068592.CrossRefPubMed Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML: Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002, 295 (5556): 858-861. 10.1126/science.1068592.CrossRefPubMed
6.
go back to reference Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK: FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002, 16 (12): 1466-1471. 10.1101/gad.991402.CrossRefPubMedPubMedCentral Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK: FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002, 16 (12): 1466-1471. 10.1101/gad.991402.CrossRefPubMedPubMedCentral
7.
go back to reference Soilleux EJ, Turley H, Tian YM, Pugh CW, Gatter KC, Harris AL: Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathology. 2005, 47 (6): 602-610. 10.1111/j.1365-2559.2005.02280.x.CrossRefPubMed Soilleux EJ, Turley H, Tian YM, Pugh CW, Gatter KC, Harris AL: Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathology. 2005, 47 (6): 602-610. 10.1111/j.1365-2559.2005.02280.x.CrossRefPubMed
8.
go back to reference Xue J, Li X, Jiao S, Wei Y, Wu G, Fang J: Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology. 2010, 138 (2): 606-615. 10.1053/j.gastro.2009.09.049.CrossRefPubMed Xue J, Li X, Jiao S, Wei Y, Wu G, Fang J: Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology. 2010, 138 (2): 606-615. 10.1053/j.gastro.2009.09.049.CrossRefPubMed
9.
go back to reference Xie G, Zheng L, Ou J, Huang H, He J, Li J, Pan F, Liang H: Low expression of prolyl hydroxylase 2 is associated with tumor grade and poor prognosis in patients with colorectal cancer. Exp Biol Med (Maywood). 2012, 237 (7): 860-866. 10.1258/ebm.2012.011331.CrossRef Xie G, Zheng L, Ou J, Huang H, He J, Li J, Pan F, Liang H: Low expression of prolyl hydroxylase 2 is associated with tumor grade and poor prognosis in patients with colorectal cancer. Exp Biol Med (Maywood). 2012, 237 (7): 860-866. 10.1258/ebm.2012.011331.CrossRef
10.
go back to reference Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, Leek R, Tan EY, Singh B, Mortensen NJ, et al: Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer. 2009, 101 (10): 1749-1757. 10.1038/sj.bjc.6605368.CrossRefPubMedPubMedCentral Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, Leek R, Tan EY, Singh B, Mortensen NJ, et al: Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer. 2009, 101 (10): 1749-1757. 10.1038/sj.bjc.6605368.CrossRefPubMedPubMedCentral
11.
go back to reference Kondo Y: Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J. 2009, 50 (4): 455-463. 10.3349/ymj.2009.50.4.455.CrossRefPubMedPubMedCentral Kondo Y: Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J. 2009, 50 (4): 455-463. 10.3349/ymj.2009.50.4.455.CrossRefPubMedPubMedCentral
12.
go back to reference Place TL, Fitzgerald MP, Venkataraman S, Vorrink SU, Case AJ, Teoh ML, Domann FE: Aberrant promoter CpG methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells. PLoS One. 2011, 6 (1): e14617-10.1371/journal.pone.0014617.CrossRefPubMedPubMedCentral Place TL, Fitzgerald MP, Venkataraman S, Vorrink SU, Case AJ, Teoh ML, Domann FE: Aberrant promoter CpG methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells. PLoS One. 2011, 6 (1): e14617-10.1371/journal.pone.0014617.CrossRefPubMedPubMedCentral
13.
go back to reference Hatzimichael E, Dasoula A, Shah R, Syed N, Papoudou-Bai A, Coley HM, Dranitsaris G, Bourantas KL, Stebbing J, Crook T: The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. Eur J Haematol. 2010, 84 (1): 47-51. 10.1111/j.1600-0609.2009.01344.x.CrossRefPubMed Hatzimichael E, Dasoula A, Shah R, Syed N, Papoudou-Bai A, Coley HM, Dranitsaris G, Bourantas KL, Stebbing J, Crook T: The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. Eur J Haematol. 2010, 84 (1): 47-51. 10.1111/j.1600-0609.2009.01344.x.CrossRefPubMed
14.
go back to reference Huang KT, Mikeska T, Dobrovic A, Fox SB: DNA methylation analysis of the HIF-1alpha prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas. Histopathology. 2010, 57 (3): 451-460. 10.1111/j.1365-2559.2010.03633.x.CrossRefPubMed Huang KT, Mikeska T, Dobrovic A, Fox SB: DNA methylation analysis of the HIF-1alpha prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas. Histopathology. 2010, 57 (3): 451-460. 10.1111/j.1365-2559.2010.03633.x.CrossRefPubMed
15.
go back to reference Durczak M, Jagodzinski PP: Apicidin upregulates PHD2 prolyl hydroxylase gene expression in cervical cancer cells. Anticancer Drugs. 2010, 21 (6): 619-624. 10.1097/CAD.0b013e328339848b.CrossRefPubMed Durczak M, Jagodzinski PP: Apicidin upregulates PHD2 prolyl hydroxylase gene expression in cervical cancer cells. Anticancer Drugs. 2010, 21 (6): 619-624. 10.1097/CAD.0b013e328339848b.CrossRefPubMed
16.
go back to reference Espina V, Mueller C, Edmiston K, Sciro M, Petricoin EF, Liotta LA: Tissue is alive: new technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics. 2009, 3 (8): 874-882.PubMedPubMedCentral Espina V, Mueller C, Edmiston K, Sciro M, Petricoin EF, Liotta LA: Tissue is alive: new technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics. 2009, 3 (8): 874-882.PubMedPubMedCentral
17.
go back to reference Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162 (1): 156-159.CrossRefPubMed Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162 (1): 156-159.CrossRefPubMed
18.
go back to reference Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3 (7): RESEARCH0034-CrossRefPubMedPubMedCentral Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3 (7): RESEARCH0034-CrossRefPubMedPubMedCentral
19.
go back to reference Sorby LA, Andersen SN, Bukholm IR, Jacobsen MB: Evaluation of suitable reference genes for normalization of real-time reverse transcription PCR analysis in colon cancer. J Exp Clin Cancer Res. 2010, 29: 144-10.1186/1756-9966-29-144.CrossRefPubMedPubMedCentral Sorby LA, Andersen SN, Bukholm IR, Jacobsen MB: Evaluation of suitable reference genes for normalization of real-time reverse transcription PCR analysis in colon cancer. J Exp Clin Cancer Res. 2010, 29: 144-10.1186/1756-9966-29-144.CrossRefPubMedPubMedCentral
23.
go back to reference Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T: BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics. 2005, 21 (21): 4067-4068. 10.1093/bioinformatics/bti652.CrossRefPubMed Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T: BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics. 2005, 21 (21): 4067-4068. 10.1093/bioinformatics/bti652.CrossRefPubMed
24.
go back to reference Rohde C, Zhang Y, Jurkowski TP, Stamerjohanns H, Reinhardt R, Jeltsch A: Bisulfite sequencing Data Presentation and Compilation (BDPC) web server–a useful tool for DNA methylation analysis. Nucleic Acids Res. 2008, 36 (5): e34-10.1093/nar/gkn083.CrossRefPubMedPubMedCentral Rohde C, Zhang Y, Jurkowski TP, Stamerjohanns H, Reinhardt R, Jeltsch A: Bisulfite sequencing Data Presentation and Compilation (BDPC) web server–a useful tool for DNA methylation analysis. Nucleic Acids Res. 2008, 36 (5): e34-10.1093/nar/gkn083.CrossRefPubMedPubMedCentral
25.
go back to reference Wojdacz TK, Dobrovic A: Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007, 35 (6): e41-10.1093/nar/gkm013.CrossRefPubMedPubMedCentral Wojdacz TK, Dobrovic A: Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007, 35 (6): e41-10.1093/nar/gkm013.CrossRefPubMedPubMedCentral
26.
go back to reference Rawluszko AA, Horbacka K, Krokowicz P, Jagodzinski PP: Decreased expression of 17-beta-hydroxysteroid dehydrogenase type 1 is associated with DNA hypermethylation in colorectal cancer located in the proximal colon. BMC Cancer. 2011, 11 (1): 522-10.1186/1471-2407-11-522.CrossRefPubMedPubMedCentral Rawluszko AA, Horbacka K, Krokowicz P, Jagodzinski PP: Decreased expression of 17-beta-hydroxysteroid dehydrogenase type 1 is associated with DNA hypermethylation in colorectal cancer located in the proximal colon. BMC Cancer. 2011, 11 (1): 522-10.1186/1471-2407-11-522.CrossRefPubMedPubMedCentral
28.
go back to reference Shao Y, Zhang W, Zhang C, Wu Q, Yang H, Zhang J, Guan M, Wan J, Yu B: High-resolution melting analysis of BLU methylation levels in gastric, colorectal, and pancreatic cancers. Cancer Invest. 2010, 28 (6): 642-648. 10.3109/07357901003631023.CrossRefPubMed Shao Y, Zhang W, Zhang C, Wu Q, Yang H, Zhang J, Guan M, Wan J, Yu B: High-resolution melting analysis of BLU methylation levels in gastric, colorectal, and pancreatic cancers. Cancer Invest. 2010, 28 (6): 642-648. 10.3109/07357901003631023.CrossRefPubMed
29.
go back to reference Dimitrakopoulos L, Vorkas PA, Georgoulias V, Lianidou ES: A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples. BMC Cancer. 2012, 12: 486-10.1186/1471-2407-12-486.CrossRefPubMedPubMedCentral Dimitrakopoulos L, Vorkas PA, Georgoulias V, Lianidou ES: A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples. BMC Cancer. 2012, 12: 486-10.1186/1471-2407-12-486.CrossRefPubMedPubMedCentral
30.
go back to reference Oster B, Thorsen K, Lamy P, Wojdacz TK, Hansen LL, Birkenkamp-Demtroder K, Sorensen KD, Laurberg S, Orntoft TF, Andersen CL: Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer. 2011, 129 (12): 2855-2866. 10.1002/ijc.25951.CrossRefPubMed Oster B, Thorsen K, Lamy P, Wojdacz TK, Hansen LL, Birkenkamp-Demtroder K, Sorensen KD, Laurberg S, Orntoft TF, Andersen CL: Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer. 2011, 129 (12): 2855-2866. 10.1002/ijc.25951.CrossRefPubMed
32.
go back to reference Brahimi-Horn MC, Chiche J, Pouyssegur J: Hypoxia and cancer. J Mol Med. 2007, 85 (12): 1301-1307. 10.1007/s00109-007-0281-3.CrossRefPubMed Brahimi-Horn MC, Chiche J, Pouyssegur J: Hypoxia and cancer. J Mol Med. 2007, 85 (12): 1301-1307. 10.1007/s00109-007-0281-3.CrossRefPubMed
33.
go back to reference Adams GE, Dische S, Fowler JF, Thomlinson RH: Hypoxic cell sensitisers in radiotherapy. Lancet. 1976, 1 (7952): 186-188.CrossRefPubMed Adams GE, Dische S, Fowler JF, Thomlinson RH: Hypoxic cell sensitisers in radiotherapy. Lancet. 1976, 1 (7952): 186-188.CrossRefPubMed
34.
go back to reference Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002, 62 (12): 3387-3394.PubMed Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002, 62 (12): 3387-3394.PubMed
35.
go back to reference Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM: Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004, 279 (37): 38458-38465. 10.1074/jbc.M406026200.CrossRefPubMed Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM: Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004, 279 (37): 38458-38465. 10.1074/jbc.M406026200.CrossRefPubMed
36.
go back to reference Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, Pezzella F, Ruszniewski P, Bedossa P: Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res. 2008, 14 (20): 6634-6639. 10.1158/1078-0432.CCR-07-5258.CrossRefPubMed Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, Pezzella F, Ruszniewski P, Bedossa P: Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res. 2008, 14 (20): 6634-6639. 10.1158/1078-0432.CCR-07-5258.CrossRefPubMed
37.
go back to reference Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL: The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res. 2005, 11 (21): 7658-7663. 10.1158/1078-0432.CCR-05-0460.CrossRefPubMed Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL: The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res. 2005, 11 (21): 7658-7663. 10.1158/1078-0432.CCR-05-0460.CrossRefPubMed
38.
go back to reference Andersen S, Donnem T, Stenvold H, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM: Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One. 2011, 6 (8): e23847-10.1371/journal.pone.0023847.CrossRefPubMedPubMedCentral Andersen S, Donnem T, Stenvold H, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM: Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One. 2011, 6 (8): e23847-10.1371/journal.pone.0023847.CrossRefPubMedPubMedCentral
39.
go back to reference Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW, Boehm JS, Ni M, Geisen C, Root DE, et al: Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009, 16 (5): 413-424. 10.1016/j.ccr.2009.09.029.CrossRefPubMedPubMedCentral Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW, Boehm JS, Ni M, Geisen C, Root DE, et al: Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009, 16 (5): 413-424. 10.1016/j.ccr.2009.09.029.CrossRefPubMedPubMedCentral
40.
go back to reference Erez N, Milyavsky M, Eilam R, Shats I, Goldfinger N, Rotter V: Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Res. 2003, 63 (24): 8777-8783.PubMed Erez N, Milyavsky M, Eilam R, Shats I, Goldfinger N, Rotter V: Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Res. 2003, 63 (24): 8777-8783.PubMed
41.
go back to reference Peurala E, Koivunen P, Bloigu R, Haapasaari KM, Jukkola-Vuorinen A: Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. Breast Cancer Res Treat. 2012, 133 (1): 179-188. 10.1007/s10549-011-1750-5.CrossRefPubMed Peurala E, Koivunen P, Bloigu R, Haapasaari KM, Jukkola-Vuorinen A: Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. Breast Cancer Res Treat. 2012, 133 (1): 179-188. 10.1007/s10549-011-1750-5.CrossRefPubMed
42.
go back to reference Jokilehto T, Rantanen K, Luukkaa M, Heikkinen P, Grenman R, Minn H, Kronqvist P, Jaakkola PM: Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res. 2006, 12 (4): 1080-1087. 10.1158/1078-0432.CCR-05-2022.CrossRefPubMed Jokilehto T, Rantanen K, Luukkaa M, Heikkinen P, Grenman R, Minn H, Kronqvist P, Jaakkola PM: Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res. 2006, 12 (4): 1080-1087. 10.1158/1078-0432.CCR-05-2022.CrossRefPubMed
43.
go back to reference Jokilehto T, Hogel H, Heikkinen P, Rantanen K, Elenius K, Sundstrom J, Jaakkola PM: Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth. Exp Cell Res. 2010, 316 (7): 1169-1178. 10.1016/j.yexcr.2010.02.012.CrossRefPubMed Jokilehto T, Hogel H, Heikkinen P, Rantanen K, Elenius K, Sundstrom J, Jaakkola PM: Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth. Exp Cell Res. 2010, 316 (7): 1169-1178. 10.1016/j.yexcr.2010.02.012.CrossRefPubMed
44.
go back to reference Gossage L, Zaitoun A, Fareed KR, Turley H, Aloysius M, Lobo DN, Harris AL, Madhusudan S: Expression of key hypoxia sensing prolyl-hydroxylases PHD1, -2 and -3 in pancreaticobiliary cancer. Histopathology. 2010, 56 (7): 908-920. 10.1111/j.1365-2559.2010.03566.x.CrossRefPubMed Gossage L, Zaitoun A, Fareed KR, Turley H, Aloysius M, Lobo DN, Harris AL, Madhusudan S: Expression of key hypoxia sensing prolyl-hydroxylases PHD1, -2 and -3 in pancreaticobiliary cancer. Histopathology. 2010, 56 (7): 908-920. 10.1111/j.1365-2559.2010.03566.x.CrossRefPubMed
45.
go back to reference Hogel H, Rantanen K, Jokilehto T, Grenman R, Jaakkola PM: Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells. PLoS One. 2011, 6 (11): e27112-10.1371/journal.pone.0027112.CrossRefPubMedPubMedCentral Hogel H, Rantanen K, Jokilehto T, Grenman R, Jaakkola PM: Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells. PLoS One. 2011, 6 (11): e27112-10.1371/journal.pone.0027112.CrossRefPubMedPubMedCentral
46.
go back to reference Su C, Huang K, Sun L, Yang D, Zheng H, Gao C, Tong J, Zhang Q: Overexpression of the HIF hydroxylase PHD3 is a favorable prognosticator for gastric cancer. Med Oncol. 2012 Su C, Huang K, Sun L, Yang D, Zheng H, Gao C, Tong J, Zhang Q: Overexpression of the HIF hydroxylase PHD3 is a favorable prognosticator for gastric cancer. Med Oncol. 2012
47.
go back to reference Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG, et al: Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005, 8 (2): 155-167. 10.1016/j.ccr.2005.06.015.CrossRefPubMed Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG, et al: Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005, 8 (2): 155-167. 10.1016/j.ccr.2005.06.015.CrossRefPubMed
48.
go back to reference Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, et al: The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008, 22 (7): 884-893. 10.1101/gad.1648608.CrossRefPubMedPubMedCentral Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, et al: The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008, 22 (7): 884-893. 10.1101/gad.1648608.CrossRefPubMedPubMedCentral
49.
go back to reference Rantanen K, Pursiheimo J, Hogel H, Himanen V, Metzen E, Jaakkola PM: Prolyl hydroxylase PHD3 activates oxygen-dependent protein aggregation. Mol Biol Cell. 2008, 19 (5): 2231-2240. 10.1091/mbc.E07-11-1124.CrossRefPubMedPubMedCentral Rantanen K, Pursiheimo J, Hogel H, Himanen V, Metzen E, Jaakkola PM: Prolyl hydroxylase PHD3 activates oxygen-dependent protein aggregation. Mol Biol Cell. 2008, 19 (5): 2231-2240. 10.1091/mbc.E07-11-1124.CrossRefPubMedPubMedCentral
50.
go back to reference D'Angelo G, Duplan E, Boyer N, Vigne P, Frelin C: Hypoxia up-regulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses during reoxygenation. J Biol Chem. 2003, 278 (40): 38183-38187. 10.1074/jbc.M302244200.CrossRefPubMed D'Angelo G, Duplan E, Boyer N, Vigne P, Frelin C: Hypoxia up-regulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses during reoxygenation. J Biol Chem. 2003, 278 (40): 38183-38187. 10.1074/jbc.M302244200.CrossRefPubMed
51.
go back to reference Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A, Fong GH: Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006, 26 (22): 8336-8346. 10.1128/MCB.00425-06.CrossRefPubMedPubMedCentral Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A, Fong GH: Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006, 26 (22): 8336-8346. 10.1128/MCB.00425-06.CrossRefPubMedPubMedCentral
52.
go back to reference Fu J, Menzies K, Freeman RS, Taubman MB: EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability. J Biol Chem. 2007, 282 (17): 12410-12418. 10.1074/jbc.M608748200.CrossRefPubMed Fu J, Menzies K, Freeman RS, Taubman MB: EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability. J Biol Chem. 2007, 282 (17): 12410-12418. 10.1074/jbc.M608748200.CrossRefPubMed
53.
go back to reference Dayan F, Roux D, Brahimi-Horn MC, Pouyssegur J, Mazure NM: The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res. 2006, 66 (7): 3688-3698. 10.1158/0008-5472.CAN-05-4564.CrossRefPubMed Dayan F, Roux D, Brahimi-Horn MC, Pouyssegur J, Mazure NM: The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res. 2006, 66 (7): 3688-3698. 10.1158/0008-5472.CAN-05-4564.CrossRefPubMed
54.
go back to reference Pelletier J, Dayan F, Durivault J, Ilc K, Pecou E, Pouyssegur J, Mazure NM: The asparaginyl hydroxylase factor-inhibiting HIF is essential for tumor growth through suppression of the p53-p21 axis. Oncogene. 2012, 31 (24): 2989-3001. 10.1038/onc.2011.471.CrossRefPubMed Pelletier J, Dayan F, Durivault J, Ilc K, Pecou E, Pouyssegur J, Mazure NM: The asparaginyl hydroxylase factor-inhibiting HIF is essential for tumor growth through suppression of the p53-p21 axis. Oncogene. 2012, 31 (24): 2989-3001. 10.1038/onc.2011.471.CrossRefPubMed
55.
go back to reference Mahon PC, Hirota K, Semenza GL: FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15 (20): 2675-2686. 10.1101/gad.924501.CrossRefPubMedPubMedCentral Mahon PC, Hirota K, Semenza GL: FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15 (20): 2675-2686. 10.1101/gad.924501.CrossRefPubMedPubMedCentral
56.
go back to reference Cockman ME, Lancaster DE, Stolze IP, Hewitson KS, McDonough MA, Coleman ML, Coles CH, Yu X, Hay RT, Ley SC, et al: Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci U S A. 2006, 103 (40): 14767-14772. 10.1073/pnas.0606877103.CrossRefPubMedPubMedCentral Cockman ME, Lancaster DE, Stolze IP, Hewitson KS, McDonough MA, Coleman ML, Coles CH, Yu X, Hay RT, Ley SC, et al: Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci U S A. 2006, 103 (40): 14767-14772. 10.1073/pnas.0606877103.CrossRefPubMedPubMedCentral
57.
go back to reference Coleman ML, McDonough MA, Hewitson KS, Coles C, Mecinovic J, Edelmann M, Cook KM, Cockman ME, Lancaster DE, Kessler BM, et al: Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J Biol Chem. 2007, 282 (33): 24027-24038. 10.1074/jbc.M704102200.CrossRefPubMed Coleman ML, McDonough MA, Hewitson KS, Coles C, Mecinovic J, Edelmann M, Cook KM, Cockman ME, Lancaster DE, Kessler BM, et al: Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J Biol Chem. 2007, 282 (33): 24027-24038. 10.1074/jbc.M704102200.CrossRefPubMed
58.
go back to reference Ferguson JE, Wu Y, Smith K, Charles P, Powers K, Wang H, Patterson C: ASB4 is a hydroxylation substrate of FIH and promotes vascular differentiation via an oxygen-dependent mechanism. Mol Cell Biol. 2007, 27 (18): 6407-6419. 10.1128/MCB.00511-07.CrossRefPubMedPubMedCentral Ferguson JE, Wu Y, Smith K, Charles P, Powers K, Wang H, Patterson C: ASB4 is a hydroxylation substrate of FIH and promotes vascular differentiation via an oxygen-dependent mechanism. Mol Cell Biol. 2007, 27 (18): 6407-6419. 10.1128/MCB.00511-07.CrossRefPubMedPubMedCentral
59.
go back to reference Fukuba H, Takahashi T, Jin HG, Kohriyama T, Matsumoto M: Abundance of aspargynyl-hydroxylase FIH is regulated by Siah-1 under normoxic conditions. Neurosci Lett. 2008, 433 (3): 209-214. 10.1016/j.neulet.2007.12.069.CrossRefPubMed Fukuba H, Takahashi T, Jin HG, Kohriyama T, Matsumoto M: Abundance of aspargynyl-hydroxylase FIH is regulated by Siah-1 under normoxic conditions. Neurosci Lett. 2008, 433 (3): 209-214. 10.1016/j.neulet.2007.12.069.CrossRefPubMed
60.
go back to reference Hu G, Fearon ER: Siah-1 N-terminal RING domain is required for proteolysis function, and C-terminal sequences regulate oligomerization and binding to target proteins. Mol Cell Biol. 1999, 19 (1): 724-732.CrossRefPubMedPubMedCentral Hu G, Fearon ER: Siah-1 N-terminal RING domain is required for proteolysis function, and C-terminal sequences regulate oligomerization and binding to target proteins. Mol Cell Biol. 1999, 19 (1): 724-732.CrossRefPubMedPubMedCentral
61.
go back to reference Bruzzoni-Giovanelli H, Fernandez P, Veiga L, Podgorniak M-P, Powell D, Candeias M, Mourah S, Calvo F, Marin M: Distinct expression patterns of the E3 ligase SIAH-1 and its partner Kid/KIF22 in normal tissues and in the breast tumoral processes. J Exp Clin Cancer Res. 2010, 29 (1): 10-10.1186/1756-9966-29-10.CrossRefPubMedPubMedCentral Bruzzoni-Giovanelli H, Fernandez P, Veiga L, Podgorniak M-P, Powell D, Candeias M, Mourah S, Calvo F, Marin M: Distinct expression patterns of the E3 ligase SIAH-1 and its partner Kid/KIF22 in normal tissues and in the breast tumoral processes. J Exp Clin Cancer Res. 2010, 29 (1): 10-10.1186/1756-9966-29-10.CrossRefPubMedPubMedCentral
62.
go back to reference Matsuo K, Satoh S, Okabe H, Nomura A, Maeda T, Yamaoka Y, Ikai I: SIAH1 inactivation correlates with tumor progression in hepatocellular carcinomas. Genes Chromosomes Cancer. 2003, 36 (3): 283-291. 10.1002/gcc.10170.CrossRefPubMed Matsuo K, Satoh S, Okabe H, Nomura A, Maeda T, Yamaoka Y, Ikai I: SIAH1 inactivation correlates with tumor progression in hepatocellular carcinomas. Genes Chromosomes Cancer. 2003, 36 (3): 283-291. 10.1002/gcc.10170.CrossRefPubMed
63.
go back to reference Wen YY, Yang ZQ, Song M, Li BL, Yao XH, Chen XL, Zhao J, Lu YY, Zhu JJ, Wang EH: The expression of SIAH1 is downregulated and associated with Bim and apoptosis in human breast cancer tissues and cells. Mol Carcinog. 2010, 49 (5): 440-449.PubMed Wen YY, Yang ZQ, Song M, Li BL, Yao XH, Chen XL, Zhao J, Lu YY, Zhu JJ, Wang EH: The expression of SIAH1 is downregulated and associated with Bim and apoptosis in human breast cancer tissues and cells. Mol Carcinog. 2010, 49 (5): 440-449.PubMed
64.
go back to reference Kim YI: Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility. J Nutr. 2005, 135 (11): 2703-2709.PubMed Kim YI: Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility. J Nutr. 2005, 135 (11): 2703-2709.PubMed
65.
go back to reference Hermann S, Rohrmann S, Linseisen J: Lifestyle factors, obesity and the risk of colorectal adenomas in EPIC-Heidelberg. Cancer Causes Control. 2009, 20 (8): 1397-1408. 10.1007/s10552-009-9366-3.CrossRefPubMed Hermann S, Rohrmann S, Linseisen J: Lifestyle factors, obesity and the risk of colorectal adenomas in EPIC-Heidelberg. Cancer Causes Control. 2009, 20 (8): 1397-1408. 10.1007/s10552-009-9366-3.CrossRefPubMed
66.
go back to reference Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 1990, 61 (5): 759-767. 10.1016/0092-8674(90)90186-I.CrossRefPubMed Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 1990, 61 (5): 759-767. 10.1016/0092-8674(90)90186-I.CrossRefPubMed
67.
go back to reference Kim MS, Lee J, Sidransky D: DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010, 29 (1): 181-206. 10.1007/s10555-010-9207-6.CrossRefPubMed Kim MS, Lee J, Sidransky D: DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010, 29 (1): 181-206. 10.1007/s10555-010-9207-6.CrossRefPubMed
68.
go back to reference Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR, Rashid A: CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol. 2002, 160 (5): 1823-1830. 10.1016/S0002-9440(10)61128-5.CrossRefPubMedPubMedCentral Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR, Rashid A: CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol. 2002, 160 (5): 1823-1830. 10.1016/S0002-9440(10)61128-5.CrossRefPubMedPubMedCentral
69.
go back to reference Suehiro Y, Hinoda Y: Genetic and epigenetic changes in aberrant crypt foci and serrated polyps. Cancer Sci. 2008, 99 (6): 1071-1076. 10.1111/j.1349-7006.2008.00784.x.CrossRefPubMed Suehiro Y, Hinoda Y: Genetic and epigenetic changes in aberrant crypt foci and serrated polyps. Cancer Sci. 2008, 99 (6): 1071-1076. 10.1111/j.1349-7006.2008.00784.x.CrossRefPubMed
70.
go back to reference Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997, 57 (5): 808-811.PubMed Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997, 57 (5): 808-811.PubMed
71.
go back to reference Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, et al: Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A. 1998, 95 (15): 8698-8702. 10.1073/pnas.95.15.8698.CrossRefPubMedPubMedCentral Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, et al: Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A. 1998, 95 (15): 8698-8702. 10.1073/pnas.95.15.8698.CrossRefPubMedPubMedCentral
72.
go back to reference Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995, 55 (20): 4525-4530.PubMed Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995, 55 (20): 4525-4530.PubMed
73.
go back to reference Pescador N, Cuevas Y, Naranjo S, Alcaide M, Villar D, Landazuri MO, Del Peso L: Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. Biochem J. 2005, 390 (Pt 1): 189-197.CrossRefPubMedPubMedCentral Pescador N, Cuevas Y, Naranjo S, Alcaide M, Villar D, Landazuri MO, Del Peso L: Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. Biochem J. 2005, 390 (Pt 1): 189-197.CrossRefPubMedPubMedCentral
74.
go back to reference Shahrzad S, Bertrand K, Minhas K, Coomber BL: Induction of DNA hypomethylation by tumor hypoxia. Epigenetics. 2007, 2 (2): 119-125. 10.4161/epi.2.2.4613.CrossRefPubMed Shahrzad S, Bertrand K, Minhas K, Coomber BL: Induction of DNA hypomethylation by tumor hypoxia. Epigenetics. 2007, 2 (2): 119-125. 10.4161/epi.2.2.4613.CrossRefPubMed
75.
go back to reference Momparler RL: Pharmacology of 5-Aza-2'-deoxycytidine (decitabine). Semin Hematol. 2005, 42 (3 Suppl 2): S9-S16.CrossRefPubMed Momparler RL: Pharmacology of 5-Aza-2'-deoxycytidine (decitabine). Semin Hematol. 2005, 42 (3 Suppl 2): S9-S16.CrossRefPubMed
76.
go back to reference Ghoshal K, Motiwala T, Claus R, Yan P, Kutay H, Datta J, Majumder S, Bai S, Majumder A, Huang T, et al: HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors. PLoS One. 2010, 5 (4): e10338-10.1371/journal.pone.0010338.CrossRefPubMedPubMedCentral Ghoshal K, Motiwala T, Claus R, Yan P, Kutay H, Datta J, Majumder S, Bai S, Majumder A, Huang T, et al: HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors. PLoS One. 2010, 5 (4): e10338-10.1371/journal.pone.0010338.CrossRefPubMedPubMedCentral
77.
go back to reference Henze AT, Riedel J, Diem T, Wenner J, Flamme I, Pouyseggur J, Plate KH, Acker T: Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Cancer Res. 2010, 70 (1): 357-366. 10.1158/0008-5472.CAN-09-1876.CrossRefPubMed Henze AT, Riedel J, Diem T, Wenner J, Flamme I, Pouyseggur J, Plate KH, Acker T: Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Cancer Res. 2010, 70 (1): 357-366. 10.1158/0008-5472.CAN-09-1876.CrossRefPubMed
78.
go back to reference Luczak MW, Jagodzinski PP: The role of DNA methylation in cancer development. Folia Histochem Cytobiol. 2006, 44 (3): 143-154.PubMed Luczak MW, Jagodzinski PP: The role of DNA methylation in cancer development. Folia Histochem Cytobiol. 2006, 44 (3): 143-154.PubMed
Metadata
Title
Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer
Authors
Agnieszka A Rawluszko
Katarzyna E Bujnicka
Karolina Horbacka
Piotr Krokowicz
Paweł P Jagodziński
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-526

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine